<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562416</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0329</org_study_id>
    <nct_id>NCT03562416</nct_id>
  </id_info>
  <brief_title>Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects</brief_title>
  <official_title>Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the utility of nintedanib therapy in addition to usual
      transplant care in single lung transplant recipients with idiopathic pulmonary fibrosis
      (IPF). The investigators hypothesize that in IPF subjects who undergo single lung
      transplantation the administration of nintedanib 150 mg twice daily in addition to usual
      transplant care will result in better preservation of lung function at 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung transplantation is the only treatment option that augments survival in patients with
      idiopathic pulmonary fibrosis (IPF). Despite several advancements in lung transplantation
      over the past three decades, long-term survival rates have remained low compared to other
      solid organ transplantations. The median survival after lung transplantation is only 5.8
      years. Multiple factors account for the relatively low survival post-transplant, but chronic
      rejection resulting in obliterative bronchiolitis is a predominate cause. Further research is
      needed to develop medical therapeutic interventions that improve survival in IPF patients who
      undergo only single lung transplantation.

      Nintedanib, a novel tyrosine kinase inhibitor, exhibits antifibrotic properties via multiple
      mechanisms including the inhibition of the receptor tyrosine kinases platelet derived growth
      factor (PDGF) receptor, fibroblast growth factor (FGF) receptor, and vascular endothelial
      growth factor (VEGF) receptor. Several mediators of pulmonary fibrosis including VEGF, FGF,
      and transforming growth factor beta (TGF-β) have also been implicated in the pathogenesis of
      bronchiolitis obliterans syndrome (BOS), the most common type of chronic lung allograft
      rejection.

      Nintedanib is safe to continue until the time of lung transplantation and has not been shown
      to worsen perioperative outcomes in small case series, single center cohorts and our center's
      personal experience. The current practice in lung transplant medicine is to discontinue
      antifibrotic therapy after lung transplantation in IPF. In IPF patients who undergo single
      lung transplant, nintedanib therapy has the potential to preserve lung function in both the
      native fibrotic lung and the new lung allograft.

      The investigators propose a randomized and placebo-controlled single center pilot trial
      comparing nintedanib therapy plus usual care to usual care only in IPF patients after single
      lung transplant. The investigators hypothesize that in IPF subjects who undergo single lung
      transplantation the administration of nintedanib 150 mg twice daily in addition to usual
      transplant care will result in better preservation of lung function at 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Change in forced expiratory volume in 1 second (FEV1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FVC</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Change in forced vital capacity (FVC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchiolitis obliterans syndrome</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Incidence of bronchiolitis obliterans syndrome (BOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchial stenosis</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Incidence of surgical anastomosis bronchial stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchial dehiscence</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Incidence of surgical anastomosis bronchial stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute cellular rejection</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Incidence of acute cellular rejection of lung allograft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug discontinuation</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Study drug discontinuation rate due to adverse drug event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug events</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Incidence of adverse drug events (i.e. elevation of liver transaminases greater than 3 times the upper limit of normal, diarrhea, nausea, vomiting, anorexia, GERD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor (VEGF) - serum</measure>
    <time_frame>Baseline to day 30</time_frame>
    <description>Change in serum biomarker concentration for VEGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor (VEGF) - BAL</measure>
    <time_frame>Baseline to day 30</time_frame>
    <description>Change in BAL concentration for VEGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor (VEGF) - serum</measure>
    <time_frame>Baseline to day 300</time_frame>
    <description>Change in serum concentration for VEGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor (VEGF) - BAL</measure>
    <time_frame>Baseline to day 300</time_frame>
    <description>Change in BAL concentration for VEGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast growth factor (FGF) - serum</measure>
    <time_frame>Baseline to day 30</time_frame>
    <description>Change in serum concentration for FGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast growth factor (FGF) - BAL</measure>
    <time_frame>Baseline to day 30</time_frame>
    <description>Change in BAL concentration for FGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast growth factor (FGF) - serum</measure>
    <time_frame>Baseline to day 300</time_frame>
    <description>Change in serum concentration for FGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast growth factor (FGF) - BAL</measure>
    <time_frame>Baseline to day 300</time_frame>
    <description>Change in BAL biomarker concentration for FGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet derived growth factor (PDGF) - serum</measure>
    <time_frame>Baseline to day 30</time_frame>
    <description>Change in serum concentration for PDGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet derived growth factor (PDGF) - BAL</measure>
    <time_frame>Baseline to day 30</time_frame>
    <description>Change in BAL biomarker concentration for PDGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet derived growth factor (PDGF) - serum</measure>
    <time_frame>Baseline to day 300</time_frame>
    <description>Change in serum biomarker concentration for PDGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet derived growth factor (PDGF) - BAL</measure>
    <time_frame>Baseline to day 300</time_frame>
    <description>Change in BAL biomarker concentration for PDGF (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood flow cytometry - CD4 T cells</measure>
    <time_frame>Day 30</time_frame>
    <description>CD4 T cell concentration in peripheral blood (cells/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood flow cytometry - CD4 T cells</measure>
    <time_frame>Day 300</time_frame>
    <description>CD4 T cell concentration in peripheral blood (cells/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood flow cytometry - CD8 T cells</measure>
    <time_frame>Day 30</time_frame>
    <description>CD8 T cell concentration in peripheral blood (cells/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood flow cytometry - CD8 T cells</measure>
    <time_frame>Day 300</time_frame>
    <description>CD8 T cell concentration in peripheral blood (cells/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood flow cytometry - macrophages</measure>
    <time_frame>Day 30</time_frame>
    <description>Macrophage concentration in peripheral blood (cells/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood flow cytometry - macrophages</measure>
    <time_frame>Day 300</time_frame>
    <description>Macrophage concentration in peripheral blood (cells/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood flow cytometry - neutrophils</measure>
    <time_frame>Day 30</time_frame>
    <description>Neutrophil concentration in peripheral blood (cells/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood flow cytometry - neutrophils</measure>
    <time_frame>Day 300</time_frame>
    <description>Neutrophil concentration in peripheral blood (cells/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>Survival and time to death/cause of death (if applicable) of study subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Lung Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Nintedanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nintedanib 150 mg tablet by mouth twice daily for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet by mouth twice daily for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Nintedanib (BIBF 1120, Ofev)</description>
    <arm_group_label>Nintedanib</arm_group_label>
    <other_name>BIBF 1120</other_name>
    <other_name>Ofev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between the ages of 35-70.

          -  Lung transplantation listing diagnosis of pulmonary fibrosis

          -  Recipient of single lung transplantation within the past 60 days

        Exclusion Criteria:

          -  History of intolerability to nintedanib (i.e. discontinued nintedanib in the
             pre-transplant period due to adverse drug effects)

          -  Liver transaminase elevation (AST or ALT &gt; 1.5X the upper limit of normal)

          -  Total bilirubin &gt; 1.5X the upper limit of normal

          -  Drugs that interfere with the metabolism or elimination of nintedanib or its
             metabolites - St. John's wort, carbamazepine, phenytoin, rifampin, dexamethasone, and
             others.

          -  Any history of bronchial anastomosis dehiscence or stenosis

          -  Bleeding risk, defined as any of the following:

               -  Full-dose therapeutic anticoagulation (i.e. vitamin K antagonist, direct thrombin
                  inhibitors, etc.)

               -  History of hemorrhagic central nervous system (CNS) event within 12 months of
                  enrollment

               -  Coagulation parameters: international normalized ratio (INR) &gt; 2, prolongation of
                  prothrombin time (PT) and partial thromboplastin time (PTT) by &gt; 1.5X the upper
                  limit of normal at enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan A Galli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francine McGonagle, BSN, RN</last_name>
    <phone>215-707-2682</phone>
    <email>Francine.McGonagle@tuhs.temple.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shubhra Srivastava-Malhotra</last_name>
    <phone>215-707-0945</phone>
    <email>Shubhra.Srivastava-Malhotra@tuhs.temple.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francine McGonagle, BSN,RN</last_name>
      <phone>215-707-2682</phone>
      <email>Francine.McGonagle@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shubhra Srivastava-Malhotra</last_name>
      <phone>215-707-0945</phone>
      <email>Shubhra.Srivastava-Malhotra@tuhs.temple.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan A Galli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard J Criner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Mulhall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kartik Shenoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Rogers, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thabut G, Mal H, Castier Y, Groussard O, Brugière O, Marrash-Chahla R, Lesèche G, Fournier M. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003 Aug;126(2):469-75.</citation>
    <PMID>12928646</PMID>
  </reference>
  <reference>
    <citation>Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, Meiser B, Rossano JW, Yusen RD, Stehlik J; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016 Oct;35(10):1158-1169. doi: 10.1016/j.healun.2016.08.017. Epub 2016 Aug 21. Review.</citation>
    <PMID>27772668</PMID>
  </reference>
  <reference>
    <citation>Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA. 2015 Mar 3;313(9):936-48. doi: 10.1001/jama.2015.1175.</citation>
    <PMID>25734735</PMID>
  </reference>
  <reference>
    <citation>Elicker BM, Golden JA, Ordovas KG, Leard L, Golden TR, Hays SR. Progression of native lung fibrosis in lung transplant recipients with idiopathic pulmonary fibrosis. Respir Med. 2010 Mar;104(3):426-33. doi: 10.1016/j.rmed.2009.10.019. Epub 2009 Nov 12.</citation>
    <PMID>19913395</PMID>
  </reference>
  <reference>
    <citation>Wahidi MM, Ravenel J, Palmer SM, McAdams HP. Progression of idiopathic pulmonary fibrosis in native lungs after single lung transplantation. Chest. 2002 Jun;121(6):2072-6.</citation>
    <PMID>12065382</PMID>
  </reference>
  <reference>
    <citation>Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015 May;45(5):1434-45. doi: 10.1183/09031936.00174914. Epub 2015 Mar 5. Review.</citation>
    <PMID>25745043</PMID>
  </reference>
  <reference>
    <citation>Xu Z, Ramachandran S, Gunasekaran M, Zhou F, Trulock E, Kreisel D, Hachem R, Mohanakumar T. MicroRNA-144 dysregulates the transforming growth factor-β signaling cascade and contributes to the development of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant. 2015 Sep;34(9):1154-62. doi: 10.1016/j.healun.2015.03.021. Epub 2015 Mar 27.</citation>
    <PMID>25979625</PMID>
  </reference>
  <reference>
    <citation>Sjoland AA, Callerfelt AK, Thiman L, et al. Prostacyclin and VEGF in the rejection process after lung transplantation-A possible biomarker [abstract]. Eur Respir J. 2016; PA4040.</citation>
  </reference>
  <reference>
    <citation>Suhling H, Bollmann B, Gottlieb J. Nintedanib in restrictive chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2016 Jul;35(7):939-40. doi: 10.1016/j.healun.2016.01.1220. Epub 2016 Feb 9.</citation>
    <PMID>26996931</PMID>
  </reference>
  <reference>
    <citation>Delanote I, Wuyts WA, Yserbyt J, Verbeken EK, Verleden GM, Vos R. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med. 2016 Nov 18;16(1):156.</citation>
    <PMID>27863518</PMID>
  </reference>
  <reference>
    <citation>Dorey-Stein Z, Galli JA, Criner GJ. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis awaiting lung transplantation [abstract]. Am J Respir Crit Care Med. 2017;195:A5386</citation>
  </reference>
  <reference>
    <citation>Leuschner G, Stocker F, Veit T, Kneidinger N, Winter H, Schramm R, Weig T, Matthes S, Ceelen F, Arnold P, Munker D, Klenner F, Hatz R, Frankenberger M, Behr J, Neurohr C. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant. 2017 Jul 5. pii: S1053-2498(17)31886-7. doi: 10.1016/j.healun.2017.07.002. [Epub ahead of print]</citation>
    <PMID>28734935</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

